{"id":"bricanyl-iprovent","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Tremor"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nervousness"},{"rate":"5-15","effect":"Dry mouth (Iprovent)"},{"rate":"2-5","effect":"Palpitations"}]},"_chembl":{"chemblId":"CHEMBL1760","moleculeType":"Small molecule","molecularWeight":"225.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Terbutaline binds to and activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation and airway dilation. This mechanism provides rapid relief of bronchoconstriction in obstructive airway diseases. Iprovent (ipratropium) is an anticholinergic agent that blocks muscarinic receptors to prevent acetylcholine-induced bronchoconstriction, often used in combination with beta-2 agonists for enhanced bronchodilation.","oneSentence":"Bricanyl (terbutaline) is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:13.366Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma"},{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Reversible airway obstruction"}]},"trialDetails":[{"nctId":"NCT01944033","phase":"PHASE3","title":"β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2013-07","conditions":"Acute Exacerbation of Chronic Obstructive Airways Disease","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bricanyl/Iprovent","genericName":"Bricanyl/Iprovent","companyName":"University of Monastir","companyId":"university-of-monastir","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bricanyl (terbutaline) is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma, Chronic obstructive pulmonary disease (COPD), Reversible airway obstruction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}